Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery. ( EpiGrid )
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNeurosoft Bioelectronics SA
About this trial
The objective of this prospective interventional monocentric clinical investigation is to evaluate the feasibility and performance of the flexible high-density SOFT ECoG electrode grids, manufactured by Neurosoft Bioelectronics SA (test device; TD), in comparison to regular high-density electrode grids (ADTech, CE-marked) (control device; CD) routinely used at the investigation site during epilepsy surgery.
Subjects will undergo ≥ 2 additional intracranial recordings pre- and post-resection with the TD next to the standard recordings with the CD during ECoG-tailored epilepsy surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years at the time of enrolment
Lesional epilepsy (incl. secondary mesial temporal sclerosis) that is considered a candidate for intra-operative high-density grid recordings (incl. patients who underwent sEEG preceding resective surgery)
Provided informed consent for study participation by the subject
Disqualifiers
Occipital lesion
Surgeries involving a primary mesial temporal lesion, a disconnection, or hemispherectomy.
Planned ioECoG recordings during fully awake surgery and/or functional recordings
Use of anticoagulants that cannot be discontinued during the perioperative period, or a factor XIII deficiency or any other haematological disease
Trial design
Design model
Single group
Treatments tested in this trial
SOFT ECoG subdural grid electrode
DeviceTest Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection. All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making.
Treatment groups
12 Participants
are divided into 1 treatment groupGroup A: All subjectsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Background SNR pre-resection recording
Performance in terms of signal quality is assessed via background signal to noise ratio (SNR). Only channels which record properly based on visual inspection (no noise, no flat line) will be included in the background SNR calculation. For the pre-resection recordings (SITUATION I/I\*), the background SNR per (included) channel and the average SNR for the electrode grid will be calculated, and pairwise comparison will be conducted between TD (SITUATION I\*) and CD (SITUATION I).
Time frame
up to 24 hoursSecondary outcomes
1
Electrode deficiency ratio (%)
The individual electrodes will be classified, per recording, as poor or good signal quality based on visual criteria (i.e., noise, flat signal due to overlap with resection cavity or silicone of secondary electrode strip, pulsation artifacts). As a result, an electrode deficiency ratio (%) will be calculated as follows: # bad electrodes divided by the total # of electrodes per recording. This will be determined for the similar positioned CD recording (SITUATION I/II) to allow comparison with the TD (SITUATION I\*/I\*\*).
Time frame
up to 24 hours2
Epileptic biomarker identification ( eg. number of spikes/HFOs per min, event SNR)
After the surgery, spikes and high frequency oscilations (HFOs) will be visually marked in the final minute of the recording (note: assisted by automated spike/HFO detector) and checked by an expert. Marking of spikes and HFOs will be done in the TD and the corresponding CD recordings pre- and post-resection. Event rates (number of spikes/HFOs per minute) per channel and total per recording will be compared between the TD and CD. The average event SNR per channel and the average SNR per epileptogenic event type will be calculated per recording. The event SNR will be compared between the CD recording (SITUATION I/II) and the TD (SITUATION I\*/I\*\*).
Time frame
up to 24 hours3
Background SNR of post-resection recordings
The background SNR for post-resection recordings (SITUATION II/II\*\*) will be computed and pairwise compared. Note that it shall be considered that for the post-resection recordings (SITUATION II/II\*\*), in particular when measuring near/in the resection cavity, the performance of both the TD and CD for electrode deficiencies might differ significantly, positively and negatively.
Time frame
up to 24 hours4
Surgical complications (e.g. SAEs/SADEs)
The safety analysis will include surgical complications in terms of device deficiencies (DDs) and serious adverse events (SAEs), and whether these are device related (SADEs).
Time frame
up to hospital discharge, on average at 10 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov